关键词: 恶性脑胶质瘤, 放射治疗, 化学治疗个性化治疗, 预后

Abstract: Objective To analysis the clinical efficacy of radiotherapy alone and concurrent chemoradiotherapy of malignant glioma after operation. Methods The retrospective study included 99 cases of malignant glioma after operation were performed in Neurosurgery Departments of Huanhu Hospital from Oct 2015 to Sept 2016. All the 99 cases of patients weredivided into two groups： radiotherapy alone group （48 cases） and concurrent chemoradiotherapy group （51 cases）. All patients began routine postoperative radiation therapy in 20 days or so, make 2 Gy/day, divided 30 times, totaling 60 Gy of radiotherapy, sustained 42 days （except Saturday and Sunday）. The concurrent chemoradiotherapy group perform the program for temozolomide 75 mg/m²·day for 42 days simultaneously; then after four weeks, the groupaccept 6 cycles of temozolomide adjuvant therapy, the program is 200 mg/m²·day, once daily for 5 days, then 23 days withdrawal, treatment may continue until disease progression, up to 2 years. The 1, 3 and 5-year survival rates of all cases were counted, and the clinical effects of radiotherapy alone and concurrent chemoradiotherapy of malignant glioma after operation were analyzed. Results 1, 3, 5-year survival rate of the radiotherapy alone group were 54.2%, 29.2%, 10.4%, and the concurrent chemoradiotherapy group were 74.5, 51.0%, 31.4%. The concurrent chemoradiotherapy group was higher than the radiotherapy alone group （P < 0.05）. The concurrent chemoradiotherapy group had higher acute reaction such asnausea and vomiting, but bone marrow suppression, hearing loss, memory loss and other long-term damages were similar in the two groups. Conclusion The concurrent chemoradiotherapy after malignant glioma operation may improve the outcome.

Key words: malignant, gliomas, radiotherapy, chemotherapy, personalized, treatment, prognosis